WallStreetZenWallStreetZen

NASDAQ: APVO
Aptevo Therapeutics Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their APVO stock forecasts and price targets.

Forecast return on equity

Is APVO forecast to generate an efficient return?
Company
127.02%
Industry
76.61%
Market
81.23%
APVO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is APVO forecast to generate an efficient return on assets?
Company
43.97%
Industry
31.22%
APVO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

APVO earnings per share forecast

What is APVO's earnings per share in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
-$8.86
Avg 2 year Forecast
-$5.77
Avg 3 year Forecast
-$3.26

APVO revenue forecast

What is APVO's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$13.2M
Avg 2 year Forecast
$57.9M
Avg 3 year Forecast
$77.1M

APVO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
APVO$0.53N/AN/A
THAR$2.82N/AN/A
INM$0.25N/AN/A
NBY$2.14N/AN/A
ADTX$1.40N/AN/A

Aptevo Therapeutics Stock Forecast FAQ

What is APVO's earnings growth forecast for 2024-2026?

(NASDAQ: APVO) Aptevo Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.34%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.95%.

Aptevo Therapeutics's earnings in 2024 is -$27,019,000.On average, 1 Wall Street analyst forecast APVO's earnings for 2024 to be -$36,150,297, with the lowest APVO earnings forecast at -$36,150,297, and the highest APVO earnings forecast at -$36,150,297. On average, 1 Wall Street analyst forecast APVO's earnings for 2025 to be -$23,542,575, with the lowest APVO earnings forecast at -$23,542,575, and the highest APVO earnings forecast at -$23,542,575.

In 2026, APVO is forecast to generate -$13,301,351 in earnings, with the lowest earnings forecast at -$13,301,351 and the highest earnings forecast at -$13,301,351.

If you're new to stock investing, here's how to buy Aptevo Therapeutics stock.

What is APVO's revenue growth forecast for 2026-2028?

(NASDAQ: APVO) Aptevo Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.7%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.86%.

Aptevo Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast APVO's revenue for 2026 to be $53,939,834, with the lowest APVO revenue forecast at $53,939,834, and the highest APVO revenue forecast at $53,939,834. On average, 1 Wall Street analysts forecast APVO's revenue for 2027 to be $236,404,992, with the lowest APVO revenue forecast at $236,404,992, and the highest APVO revenue forecast at $236,404,992.

In 2028, APVO is forecast to generate $314,744,237 in revenue, with the lowest revenue forecast at $314,744,237 and the highest revenue forecast at $314,744,237.

What is APVO's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: APVO) forecast ROA is 43.97%, which is higher than the forecast US Biotechnology industry average of 31.22%.

What is APVO's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: APVO) Aptevo Therapeutics's current Earnings Per Share (EPS) is -$92.23. On average, analysts forecast that APVO's EPS will be -$8.86 for 2024, with the lowest EPS forecast at -$8.86, and the highest EPS forecast at -$8.86. On average, analysts forecast that APVO's EPS will be -$5.77 for 2025, with the lowest EPS forecast at -$5.77, and the highest EPS forecast at -$5.77. In 2026, APVO's EPS is forecast to hit -$3.26 (min: -$3.26, max: -$3.26).

What is APVO's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: APVO) forecast ROE is 127.02%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.